Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Springer full text link Springer Free PMC article
Full text links

Actions

Share

Review
doi: 10.1007/s40265-016-0670-4.

Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease

Affiliations
Review

Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease

Emma M Coppen et al. Drugs.2017 Jan.

Abstract

There are currently no effective pharmacological agents available to stop or prevent the progression of Huntington's disease (HD), a rare hereditary neurodegenerative disorder. In addition to psychiatric symptoms and cognitive impairments, HD causes progressive motor disturbances, in particular choreiform movements, which are characterized by unwanted contractions of the facial muscles, trunk and extremities. Management of choreiform movements is usually advised if chorea interferes with daily functioning, causes social isolation, gait instability, falls, or physical injury. Although drugs to reduce chorea are available, only few randomized controlled studies have assessed the efficacy of these drugs, resulting in a high variety of prescribed drugs in clinical practice. The current pharmacological treatment options to reduce chorea in HD are outlined in this review, including the latest results on deutetrabenazine, a newly developed pharmacological agent similar to tetrabenazine, but with suggested less peak dose side effects. A review of the existing literature was conducted using the PubMed, Cochrane and Medline databases. In conclusion, mainly tetrabenazine, tiapride (in European countries), olanzapine, and risperidone are the preferred first choice drugs to reduce chorea among HD experts. In the existing literature, these drugs also show a beneficial effect on motor symptom severity and improvement of psychiatric symptoms. Generally, it is recommended to start with a low dose and increase the dose with close monitoring of any adverse effects. New interesting agents, such as deutetrabenazine and pridopidine, are currently under development and more randomized controlled trials are warranted to assess the efficacy on chorea severity in HD.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical Standards Funding None. Conflict of interest EM Coppen has no conflicts of interest to declare. R. A. C. Roos received research grants from the CHDI Foundation, Gossweiler Foundation, and Teva Pharmaceutical Industries, Ltd.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Roos RAC. Huntington’s disease: a clinical review. Orphanet J Rare Dis. 2010;5:40. doi: 10.1186/1750-1172-5-40. - DOI - PMC - PubMed
    1. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington’s disease. Cochrane Database Syst Rev. 2009;(3):CD006456. doi:10.1002/14651858.CD006456.pub2. - PubMed
    1. Jankovic J, Roos RAC. Chorea associated with Huntington’s disease: to treat or not to treat? Mov Disord. 2014;29:1414–1418. doi: 10.1002/mds.25996. - DOI - PubMed
    1. The Huntington’s Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971–983. doi: 10.1016/0092-8674(93)90585-E. - DOI - PubMed
    1. De la Monte S, Vonsattel J, Richardson E. Morphometric demonstration of atrophic changes in cerebral cortex, white matter and neostriatum in Huntington’s disease. J Neuropathol Exp Neurol. 1988;47:516–525. doi: 10.1097/00005072-198809000-00003. - DOI - PubMed

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full text links
Springer full text link Springer Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp